文献速递淋巴瘤造血干细胞移植与细胞治疗

局部放疗通过增强抗原交叉呈递和T细胞浸润提升系统性CAR T细胞疗效

Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration.
PubMed 文献 · Blood Adv · 2024-01-01

该研究在A20淋巴瘤小鼠模型中探讨1至2次低剂量分次放疗对CD19 CAR T细胞(CART-19)疗效的影响,发现放疗联合CART-19对受照肿瘤生长产生叠加效应,且未受照肿瘤抗肿瘤效应显著额外增加;机制涉及环鸟苷酸腺苷酸合成酶/干扰素基因刺激因子通路激活、肿瘤相关抗原交叉致敏及表位扩展。作者认为放疗可能作为CAR T细胞治疗的最佳启动和桥接方式。

要点

  • 低剂量分次放疗对受照部位之外的全身抗肿瘤效应(远隔效应)有正向作用。
  • 放疗联合CART-19对受照肿瘤生长产生叠加效应,未受照肿瘤抗肿瘤效应显著额外增加。
  • 机制涉及环鸟苷酸腺苷酸合成酶/干扰素基因刺激因子通路激活、抗原交叉致敏和表位扩展。

核心结论

  • 作者认为放疗可能作为CAR T细胞治疗的最佳启动和桥接方式,克服治疗耐药并改善CD19阳性血液系统恶性肿瘤患者的临床结局。

研究设计与样本

  • 研究采用A20淋巴瘤细胞建立小鼠模型,用于CART-19治疗研究,以探讨1至2次低剂量分次放疗对CART-19治疗反应的影响。

主要发现

  • 低剂量分次放疗对受照部位之外的全身抗肿瘤远隔效应有正向作用。
  • 放疗联合CART-19对受照肿瘤生长产生叠加效应。
  • 未受照肿瘤中观察到抗肿瘤效应显著额外增加。
  • 机制验证了环鸟苷酸腺苷酸合成酶/干扰素基因刺激因子通路激活、肿瘤相关抗原交叉致敏及表位扩展。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CART-19) represents a significant advance in the treatment of patients with relapsed or refractory CD19+ B-cell lymphomas. However, a significant portion of patients either relapse or fail to respond. Moreover, many patients have symptomatic disease, requiring bridging radiation therapy (RT) during the period of CAR T-cell manufacturing. To investigate the impact of 1 to 2 fractions of low-dose RT on CART-19 treatment response, we developed a mouse model using A20 lymphoma cells for CART-19 therapy. We found that low-dose fractionated RT had a positive effect on generating abscopal systemic antitumor responses beyond the irradiated site. The combination of RT with CART-19 therapy resulted in additive effects on tumor growth in irradiated masses. Notably, a significant additional increase in antitumor effect was observed in nonirradiated tumors. Mechanistically, our results validate activation of the cyclic guanosine adenosine synthetase/stimulator of interferon genes pathway, tumor-associated antigen crosspriming, and elicitation of epitope spreading. Collectively, our findings suggest that RT may serve as an optimal priming and bridging modality for CAR T-cell therapy, overcoming treatment resistance and improving clinical outcomes in patients with CD19+ hematologic malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kostopoulos N, Costabile F, Krimitza E, et al. Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv. 2024. PMID: 39213422. doi:10.1182/bloodadvances.2024012599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。